<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="urn:hl7-org:v3" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="33504c5f-664b-4f6b-e063-6294a90a2aea"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use OMLONTI 
 <sup>®</sup>safely and effectively. See full prescribing information for OMLONTI 
 <sup>®</sup>.
 <br/>
      <br/>
OMLONTI 
 <sup>®</sup>(omidenepag isopropyl ophthalmic solution) 0.002%, for topical ophthalmic use
 <br/>
Initial U.S. Approval: 2022
</title>
   <effectiveTime value="20250421"/>
   <setId root="4258e437-7e92-4b09-baf1-01cb158cfc05"/>
   <versionNumber value="3"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="119365132"/>
            <name>Ocuvex Therapeutics, Inc.</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="335053e8-a75a-4090-e063-6394a90aab7a"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250421"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="84826-002" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Omlonti</name>
                        <formCode code="C60992" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SOLUTION/ DROPS"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>omidenepag isopropyl</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROCHLORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="0.02"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="G0G0H52U6K" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>OMIDENEPAG ISOPROPYL</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="Z95F9F9LU4" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>OMIDENEPAG</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="2.5" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43173" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, PLASTIC"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="84826-002-01" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20250428"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102835" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="2.5" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43173" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, PLASTIC"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="3" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="84826-002-03" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20250428"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102835" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA215092" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20220923"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38287" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OPHTHALMIC"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="S1">
               <id root="335033bf-68e3-2053-e063-6394a90a4ef2"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>Omlonti (omidenepag isopropyl ophthalmic solution) 0.002%, is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.</paragraph>
               </text>
               <effectiveTime value="20241031"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Omlonti (omidenepag isopropyl ophthalmic solution) 0.002%, is a relatively selective prostaglandin E2 (EP2) receptor agonist, indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. (
 
    <linkHtml href="#S1">1</linkHtml>)

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S2">
               <id root="335033bf-68e4-2053-e063-6394a90a4ef2"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20241031"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The recommended dosage is one drop in the affected eye(s) once daily in the evening. (
 
    <linkHtml href="#S2.1">2.1</linkHtml>)

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S2.1">
                     <id root="335033bf-68e5-2053-e063-6394a90a4ef2"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Recommended Dosage</title>
                     <text>
                        <paragraph>The recommended dosage is one drop in the affected eye(s) once daily in the evening.</paragraph>
                     </text>
                     <effectiveTime value="20241031"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.2">
                     <id root="335033bf-68e6-2053-e063-6394a90a4ef2"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Administration Instructions</title>
                     <text>
                        <paragraph>Gently shake the bottle prior to administration. If more than one topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes apart. Contact lenses should be removed prior to the administration of Omlonti, and may be reinserted 15 minutes after administration
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S17">Patient Counseling Information (17)</linkHtml>].
 
  </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20241031"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S3">
               <id root="335033bf-68e7-2053-e063-6394a90a4ef2"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Omidenepag isopropyl ophthalmic solution: 0.002% (0.02 mg/mL)</paragraph>
               </text>
               <effectiveTime value="20241031"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Ophthalmic solution containing 0.002% (0.02 mg/mL) of omidenepag isopropyl. (
 
    <linkHtml href="#S3">3</linkHtml>)

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S4">
               <id root="335033bf-68e8-2053-e063-6394a90a4ef2"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>None.</paragraph>
               </text>
               <effectiveTime value="20241031"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>None (
 
    <linkHtml href="#S4">4</linkHtml>)

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S5">
               <id root="335033bf-68e9-2053-e063-6394a90a4ef2"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20241031"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Pigmentation (
  
     <linkHtml href="#S5.1">5.1</linkHtml>)
 
    </item>
                           <item>Eyelash changes (
  
     <linkHtml href="#S5.2">5.2</linkHtml>)
 
    </item>
                           <item>Ocular Inflammation (
  
     <linkHtml href="#S5.3">5.3</linkHtml>)
 
    </item>
                           <item>Macular Edema (
  
     <linkHtml href="#S5.4">5.4</linkHtml>)
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S5.1">
                     <id root="335033bf-68ea-2053-e063-6394a90a4ef2"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Pigmentation</title>
                     <text>
                        <paragraph>Omlonti (omidenepag isopropyl ophthalmic solution) 0.002%, is a prodrug of omidenepag, a relatively selective EP2 receptor agonist. Pigmentation is expected to increase as long as omidenepag isopropyl ophthalmic solution is administered. The pigmentation change is due to increased melanin content in the melanocytes rather than to an increase in the number of melanocytes. After discontinuation of Omlonti, pigmentation of the iris is likely to be permanent, while pigmentation of the periorbital tissue and eyelash changes are likely to be reversible in most patients. Patients who receive prostaglandin analogs, including Omlonti, should be informed of the possibility of increased pigmentation, including permanent changes. The long-term effects of increased pigmentation are not known.</paragraph>
                        <paragraph>Iris color change may not be noticeable for several months to years. Typically, the brown pigmentation around the pupil spreads concentrically towards the periphery of the iris and the entire iris or parts of the iris become more brownish. Neither nevi nor freckles of the iris appear to be affected by treatment. While treatment with Omlonti (omidenepag isopropyl ophthalmic solution), 0.002% can be continued in patients who develop noticeably increased iris pigmentation, these patients should be examined regularly
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S17">Patient Counseling Information (17)</linkHtml>]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20241031"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.2">
                     <id root="335033bf-68eb-2053-e063-6394a90a4ef2"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Eyelash Changes</title>
                     <text>
                        <paragraph>Omlonti may gradually change eyelashes and vellus hair in the treated eye. These changes include increased length, thickness, and the number of lashes or hairs. Eyelash changes are usually reversible upon discontinuation of treatment.</paragraph>
                     </text>
                     <effectiveTime value="20241031"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.3">
                     <id root="335033bf-68ec-2053-e063-6394a90a4ef2"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Ocular Inflammation</title>
                     <text>
                        <paragraph>Ocular inflammation has been reported in patients taking Omlonti. Omlonti should be used with caution in patients with active ocular inflammation, including iritis/uveitis.</paragraph>
                     </text>
                     <effectiveTime value="20241031"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.4">
                     <id root="335033bf-68ed-2053-e063-6394a90a4ef2"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Macular Edema</title>
                     <text>
                        <paragraph>Macular edema, including cystoid macular edema, has been reported during clinical trials in patients with pseudophakia receiving Omlonti. Omlonti should be used with caution in aphakic patients, in pseudophakic patients, or in patients with known risk factors for macular edema.</paragraph>
                     </text>
                     <effectiveTime value="20241031"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.5">
                     <id root="335033bf-68ee-2053-e063-6394a90a4ef2"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5 Risk of Contamination and Potential Injury to the Eye</title>
                     <text>
                        <paragraph>Advise patients to avoid touching the tip of the bottle to the eye or any surface, as this may contaminate the solution. Advise patients to not touch the tip to their eye to avoid the potential for injury to the eye.</paragraph>
                     </text>
                     <effectiveTime value="20241031"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S6">
               <id root="335033bf-68ef-2053-e063-6394a90a4ef2"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following clinically significant adverse reactions are described elsewhere in the labeling:</paragraph>
                  <list listType="unordered">
                     <item>Pigmentation
  
   <content styleCode="italics">[see
   
    <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]
  
   </content>
                     </item>
                     <item>Eyelash Changes
  
   <content styleCode="italics">[see
   
    <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]
  
   </content>
                     </item>
                     <item>Ocular Inflammation
  
   <content styleCode="italics">[see
   
    <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>]
  
   </content>
                     </item>
                     <item>Macular Edema
  
   <content styleCode="italics">[see
   
    <linkHtml href="#S5.4">Warnings and Precautions (5.4)</linkHtml>]
  
   </content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20241031"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The most common adverse reactions with incidence ≥ 1% are conjunctival hyperemia (9%), photophobia (5%), vision blurred (4%), dry eye (3%), instillation site pain (3%), eye pain (2%), ocular hyperemia (2%), punctate keratitis (2%), headache (2%), eye irritation (1%), and visual impairment (1%). (
 
    <linkHtml href="#S6.1">6.1</linkHtml>)

   </paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Ocuvex at 1-877-622-9326 or FDA at 1-800-FDA-1088 or
  
     <content styleCode="underline">
                                 <linkHtml href="https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program">www.fda.gov/medwatch</linkHtml>
                              </content>.
 
    </content>
                        </paragraph>
                        <br/>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S6.1">
                     <id root="335033bf-68f0-2053-e063-6394a90a4ef2"/>
                     <code code="90374-0" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL TRIALS EXPERIENCE SECTION"/>
                     <title>6.1 Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>The data described below reflect exposure to Omlonti in 600 patients for up to 3 months
 
  <content styleCode="italics">.</content>The most common adverse reactions with incidence ≥ 1% are conjunctival hyperemia (9%), photophobia (5%), vision blurred (4%), dry eye (3%), instillation site pain (3%), eye pain (2%), ocular hyperemia (2%), punctate keratitis (2%), headache (2%), eye irritation (1%), and visual impairment (1%).

 </paragraph>
                     </text>
                     <effectiveTime value="20241031"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S8">
               <id root="335033bf-68f1-2053-e063-6394a90a4ef2"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20241031"/>
               <component>
                  <section ID="S8.1">
                     <id root="335033bf-68f2-2053-e063-6394a90a4ef2"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <effectiveTime value="20241031"/>
                     <component>
                        <section>
                           <id root="335033bf-68f3-2053-e063-6394a90a4ef2"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>There are no available data on the use of Omlonti in pregnant women. In animal reproduction studies, subcutaneous administration of omidenepag isopropyl to pregnant rabbits throughout the period of organogenesis produced fetal skeletal anomalies at a dose of 24 times the clinical dose, based on estimated plasma C
 
  <sub>max</sub>. Omidenepag isopropyl was not teratogenic in rats when administered subcutaneously at 1 mg/kg/day, 2,452 times the clinical dose, based on estimated plasma C
 
  <sub>max</sub>
                                 <content styleCode="italics">(see
  
   <linkHtml href="#data">Data</linkHtml>)
 
  </content>.

 </paragraph>
                           </text>
                           <effectiveTime value="20241031"/>
                        </section>
                     </component>
                     <component>
                        <section ID="data">
                           <id root="335033bf-68f4-2053-e063-6394a90a4ef2"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Data</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20241031"/>
                           <component>
                              <section>
                                 <id root="335033bf-68f5-2053-e063-6394a90a4ef2"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Animal Data</content>
                                    </paragraph>
                                    <paragraph>An embryofetal development study was conducted in pregnant rabbits administered omidenepag isopropyl once daily by subcutaneous injection at 0.008, 0.08, or 0.8 mg/kg/day from gestation Day 6 to 18, a period which covers implantation and the period of organogenesis in rabbits. Fetal skeletal anomalies (thoracic misaligned centrum and hemivertebra, fused sternebra, absent rib) were observed at 0.008 mg/kg/day (24 times the maximum recommended human ocular dose [MRHOD], based on estimated plasma C
 
  <sub>max</sub>). Additional fetal skeletal anomalies were observed at 0.08 mg/kg (absent thoracic arch, fused rib) and 0.8 mg/kg (misaligned and misshapen cervical vertebrae), corresponding to 256 times and 3,696 times the MRHOD based on estimated plasma C
 
  <sub>max</sub>, respectively. Increases in preimplantation loss and post-implantation loss were observed at 0.8 mg/kg/day. The rabbit maternal, No Observed Adverse Effect Level [NOAEL] was 0.8 mg/kg/day.

 </paragraph>
                                    <paragraph>An embryofetal development study was conducted in pregnant rats administered omidenepag isopropyl once daily by subcutaneous injection at 0.01, 0.1, or 1 mg/kg/day from gestation Day 6 to 17, to target the period of organogenesis. Omidenepag isopropyl was not found to have any effect on embryo-fetal development in rats at up to 1 mg/kg/day (2,452 times the MRHOD based on estimated plasma C
 
  <sub>max</sub>). The rat maternal NOAEL was 1 mg/kg/day. In a pre/postnatal development study, treatment of pregnant rats with omidenepag isopropyl subcutaneously from gestation day 6 to lactation day 20 at 0.01, 0.1, or 1 mg/kg/day resulted in no adverse effects. The NOAEL for pre- and postnatal development was 1 mg/kg/day (2,452 times the MRHOD based on estimated plasma C
 
  <sub>max</sub>).

 </paragraph>
                                 </text>
                                 <effectiveTime value="20241031"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.2">
                     <id root="335033bf-68f6-2053-e063-6394a90a4ef2"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <effectiveTime value="20241031"/>
                     <component>
                        <section>
                           <id root="335033bf-68f7-2053-e063-6394a90a4ef2"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>There are no data on the presence of Omlonti in human milk, the effects on the breastfed infant, or the effects on milk production. However, systemic exposure to omidenepag following topical ocular administration is low
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>],
 
  </content>and it is not known whether measurable levels of omidenepag would be present in maternal milk following topical ocular administration. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Omlonti and any unknown potential adverse effects on the breast-fed child from Omlonti.

 </paragraph>
                           </text>
                           <effectiveTime value="20241031"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.3">
                     <id root="335033bf-68f8-2053-e063-6394a90a4ef2"/>
                     <code code="77291-3" codeSystem="2.16.840.1.113883.6.1" displayName="FEMALES &amp; MALES OF REPRODUCTIVE POTENTIAL SECTION"/>
                     <title>8.3 Females and Males of Reproductive Potential</title>
                     <effectiveTime value="20241031"/>
                     <component>
                        <section>
                           <id root="335033bf-68f9-2053-e063-6394a90a4ef2"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Infertility</content>
                              </paragraph>
                              <paragraph>There are no data on the effects of Omlonti on human fertility. No impairment of fertility has been reported in animals receiving omidenepag isopropyl subcutaneously at doses up to 2,452 times the clinical dose based on estimated plasma C
 
  <sub>max</sub>
                                 <content styleCode="italics">[see
  
   <linkHtml href="#S13.1">Nonclinical Toxicology (13.1)</linkHtml>]
 
  </content>.

 </paragraph>
                           </text>
                           <effectiveTime value="20241031"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.4">
                     <id root="335033bf-68fa-2053-e063-6394a90a4ef2"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>The safety and effectiveness of Omlonti have not been established in pediatric patients.</paragraph>
                     </text>
                     <effectiveTime value="20241031"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.5">
                     <id root="335033bf-68fb-2053-e063-6394a90a4ef2"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>No overall differences in safety or effectiveness have been observed between elderly and other adult patients.</paragraph>
                     </text>
                     <effectiveTime value="20241031"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S11">
               <id root="335033bf-68fc-2053-e063-6394a90a4ef2"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>Omlonti (omidenepag isopropyl ophthalmic solution) 0.002%, contains the prodrug form of the active omidenepag, a relatively selective prostaglandin EP2 receptor agonist with ocular hypotensive activity. Omidenepag isopropyl is a white to light brown crystal or crystalline powder and practically insoluble in water. Omidenepag isopropyl's chemical name is Glycine, N-[6-[[[[4-(1H-pyrazol-1-yl)phenyl]methyl](3-pyridinylsulfonyl)amino]methyl]-2-pyridinyl]-, 1-methylethyl ester and has the following structure:</paragraph>
                  <paragraph>
                     <content styleCode="bold">Structural Formula</content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM28"/>
                  </paragraph>
                  <paragraph>Formula of the free base: C
 
  <sub>26</sub>H
 
  <sub>28</sub>N
 
  <sub>6</sub>O
 
  <sub>4</sub>S. Molecular weight: 520.61

 </paragraph>
                  <paragraph>Omlonti appears as a clear, colorless solution. It is supplied as a sterile, isotonic, buffered aqueous solution of omidenepag isopropyl with a target pH of 5.8 and an osmolality of approximately 285 mOsmol/kg.</paragraph>
                  <paragraph>Each mL of Omlonti contains: Active: 0.02 mg of omidenepag isopropyl.</paragraph>
                  <paragraph>Preservative: 0.005% benzalkonium chloride.</paragraph>
                  <paragraph>Inactive ingredients: glycerin, polyoxyl 35 castor oil, sodium citrate, citric acid monohydrate, edetate disodium, sodium hydroxide and/or hydrochloric acid (to adjust pH), and water for injection.</paragraph>
               </text>
               <effectiveTime value="20241031"/>
               <component>
                  <observationMedia ID="MM28">
                     <text>Chemical Structure</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="omlonti-ophthalmic-solution-structure.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="S12">
               <id root="335033bf-68fd-2053-e063-6394a90a4ef2"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20241031"/>
               <component>
                  <section ID="S12.1">
                     <id root="335033bf-68fe-2053-e063-6394a90a4ef2"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Omidenepag is a relatively selective EP2 receptor agonist which decreases intraocular pressure (IOP). The exact mechanism of action is unknown at this time. Elevated IOP represents a major risk factor for glaucomatous field loss. The higher the level of IOP, the greater the likelihood of optic nerve damage and visual field loss.</paragraph>
                     </text>
                     <effectiveTime value="20241031"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.3">
                     <id root="335033bf-68ff-2053-e063-6394a90a4ef2"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <effectiveTime value="20241031"/>
                     <component>
                        <section>
                           <id root="335033bf-6900-2053-e063-6394a90a4ef2"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Absorption</content>
                              </paragraph>
                              <paragraph>Omlonti is absorbed through the cornea where prodrug omidenepag isopropyl is hydrolyzed to become biologically active metabolite, omidenepag. After once daily ocular administration of one drop of omidenepag isopropyl 0.0025% eye drops to both eyes in humans for 7 days, plasma concentrations of omidenepag reached C
 
  <sub>max</sub>at 10-15 minutes. Systemic exposure was similar between days 1 and 7, indicating no systemic accumulation.

 </paragraph>
                           </text>
                           <effectiveTime value="20241031"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="335033bf-6901-2053-e063-6394a90a4ef2"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Elimination</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20241031"/>
                           <component>
                              <section>
                                 <id root="335033bf-6902-2053-e063-6394a90a4ef2"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Metabolism</content>
                                    </paragraph>
                                    <paragraph>After topical ocular administration, omidenepag isopropyl is rapidly metabolized in the eye to omidenepag (active moiety) by carboxylesterase-1. The pharmacologically active form, omidenepag is further metabolized by liver through oxidation,
 
  <content styleCode="italics">N</content>-dealkylation, glucuronidation, sulfate conjugation or taurine conjugation.

 </paragraph>
                                 </text>
                                 <effectiveTime value="20241031"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="335033bf-6903-2053-e063-6394a90a4ef2"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Excretion</content>
                                    </paragraph>
                                    <paragraph>In rats, 0.03%
 
  <sup>14</sup>C-Omlonti was instilled in both eyes as a single dose (5 mcL/eye, 3 mcg/animal). By 168 hours after ocular instillation, 89% of the administered radioactive dose had been excreted. Specifically, 83% and 4% of the administered radioactive dose were excreted in the feces and urine, respectively, and radioactivity in expired air was below the lower limit of quantitation.

 </paragraph>
                                 </text>
                                 <effectiveTime value="20241031"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S13">
               <id root="335033bf-6904-2053-e063-6394a90a4ef2"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20241031"/>
               <component>
                  <section ID="S13.1">
                     <id root="335033bf-6905-2053-e063-6394a90a4ef2"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <effectiveTime value="20241031"/>
                     <component>
                        <section>
                           <id root="335033bf-6906-2053-e063-6394a90a4ef2"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Carcinogenesis</content>
                              </paragraph>
                              <paragraph>Lifetime rodent studies have not been performed to evaluate the carcinogenic potential of omidenepag isopropyl or omidenepag.</paragraph>
                              <paragraph>In rats dosed by subcutaneous injection daily for 26 weeks, nephroblastoma and a spermatic cord tumor were found at 0.003 mg/kg/day (33 times the RHOD based on the estimated area under the curve [AUC]). Mammary adenocarcinoma and pituitary pars distalis adenomas were observed at 0.03 mg/kg/day (319 fold the RHOD based on the estimated AUC).</paragraph>
                           </text>
                           <effectiveTime value="20241031"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="335033bf-6907-2053-e063-6394a90a4ef2"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Mutagenesis</content>
                              </paragraph>
                              <paragraph>Omidenepag was not mutagenic in the bacterial reverse mutation (Ames) test and the
 
  <content styleCode="italics">in vivo</content>mouse micronucleus test. Omidenepag isopropyl was positive (mutagenic and clastogenic) without metabolic activation in the
 
  <content styleCode="italics">in vitro</content>mouse lymphoma forward mutation assay.
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]
 
  </content>.

 </paragraph>
                           </text>
                           <effectiveTime value="20241031"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="335033bf-6908-2053-e063-6394a90a4ef2"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Impairment of Fertility</content>
                              </paragraph>
                              <paragraph>In a rat fertility and early embryonic development study, daily subcutaneous doses of omidenepag isopropyl did not affect male or female fertility at doses up to 1 mg/kg/day (2,452 times the MRHOD based on estimated plasma C
 
  <sub>max</sub>).

 </paragraph>
                              <paragraph>The rabbit embryofetal development study administered omidenepag isopropyl to pregnant rabbits beginning on gestation day 6, covering the period of implantation
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S8.1">Use in Specific Populations (8.1)</linkHtml>]
 
  </content>. Preimplantation losses were observed at 0.8 mg/kg/day (3,696 times the MRHOD based on estimated plasma C
 
  <sub>max</sub>). The NOAEL for rabbit preimplantation loss was 0.08 mg/kg/day (256 times the MHROD based on estimated plasma C
 
  <sub>max</sub>)
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S8.1">Use in Specific Populations (8.1)</linkHtml>]
 
  </content>.

 </paragraph>
                           </text>
                           <effectiveTime value="20241031"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S13.2">
                     <id root="335033bf-6909-2053-e063-6394a90a4ef2"/>
                     <code code="34091-9" codeSystem="2.16.840.1.113883.6.1" displayName="ANIMAL PHARMACOLOGY &amp; OR TOXICOLOGY SECTION"/>
                     <title>13.2 Animal Toxicology and/or Pharmacology</title>
                     <text>
                        <paragraph>Nasal cavity respiratory epithelium metaplasia was observed in cynomolgus monkeys receiving unilateral topical ocular instillations of omidenepag isopropyl at 0.003% (0.9 mcg/eye) [1.07 fold the MRHOD, based on ocular dose comparison]. In a 13-week monkey study, the 0.9 mcg/eye dose was associated with nasal cavity respiratory epithelial metaplasia, and increased nasal cavity goblet cell respiratory epithelium mucosa. In a 39-week monkey study, the 0.9 mcg/eye dose was associated with increased incidence and severity of nasal cavity respiratory epithelium metaplasia. These findings were present in both the treated side and untreated contralateral side, and they were also observed in the vehicle group
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S6">Adverse Reactions (6)</linkHtml>]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20241031"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S14">
               <id root="335033bf-690a-2053-e063-6394a90a4ef2"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <text>
                  <paragraph>Omlonti was evaluated in three randomized and controlled clinical trials in subjects with open-angle glaucoma or ocular hypertension with average baseline IOP of 24-26 mm Hg. The double-masked treatment duration was 3 months in all 3 studies. The third study included a 9-month open-label treatment period following the 3-month double-masked treatment period.</paragraph>
                  <paragraph>In the three studies, IOP reductions were observed for all treatment arms. In the Omlonti arm, the reduction in IOP ranged from 5-7 mm Hg across all three studies. The corresponding reductions for the timolol and latanoprost arms were 5-7 mm Hg and 6-8 mm Hg, respectively.</paragraph>
               </text>
               <effectiveTime value="20241031"/>
            </section>
         </component>
         <component>
            <section ID="S16">
               <id root="335033bf-690b-2053-e063-6394a90a4ef2"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>Omlonti (omidenepag isopropyl ophthalmic solution) 0.002%, is supplied as a 2.5 mL sterile solution in 5 mL white low density polyethylene bottles with linear low density polyethylene dropper tips, high density polyethylene screw caps and tamper-evident low density polyethylene overcaps.</paragraph>
                  <paragraph>Package of 1 bottle, NDC 84826-002-01</paragraph>
                  <paragraph>Multi-pack of 3 bottles, NDC 84826-002-03</paragraph>
               </text>
               <effectiveTime value="20241031"/>
               <component>
                  <section>
                     <id root="335033bf-690c-2053-e063-6394a90a4ef2"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <text>
                        <paragraph>Storage: Store unopened bottle (s) in the refrigerator at 2°C to 8°C (36°F to 46°F). Once a bottle is opened for use, it can be stored for up to 31 days at up to 30°C (86°F).</paragraph>
                     </text>
                     <effectiveTime value="20241031"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S17">
               <id root="335033bf-690d-2053-e063-6394a90a4ef2"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>Advise the patient to read the FDA-approved patient labeling (Instructions for Use).</paragraph>
               </text>
               <effectiveTime value="20241031"/>
               <component>
                  <section>
                     <id root="335033bf-690e-2053-e063-6394a90a4ef2"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Potential for Pigmentation</content>
                        </paragraph>
                        <paragraph>Patients should be advised about the potential for increased brown pigmentation of the iris, which may be permanent. Patients should also be informed about the possibility of eyelid skin darkening, which is usually reversible after discontinuation of Omlonti.</paragraph>
                     </text>
                     <effectiveTime value="20241031"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="335033bf-690f-2053-e063-6394a90a4ef2"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Potential for Eyelash Changes</content>
                        </paragraph>
                        <paragraph>Patients should also be informed of the possibility of eyelash and vellus hair changes in the treated eye during treatment with Omlonti. These changes may result in a disparity between eyes in length, thickness, pigmentation, number of eyelashes or vellus hairs, and/or direction of eyelash growth. Eyelash changes are usually reversible upon discontinuation of treatment.</paragraph>
                     </text>
                     <effectiveTime value="20241031"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="335033bf-6910-2053-e063-6394a90a4ef2"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Handling the Container</content>
                        </paragraph>
                        <paragraph>Advise patients to avoid touching the tip of the bottle to the eye or any surface, as this may contaminate the solution. Advise patients to not touch the tip to their eye to avoid the potential for injury to the eye. The product should be refrigerated before opening, and once it is opened, it can be stored at room temperature for up to 31 days
 
  <content styleCode="italics">. [see
  
   <linkHtml href="#S16">How Supplied/Storage and Handling (16)</linkHtml>]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20241031"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="335033bf-6911-2053-e063-6394a90a4ef2"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">When to Seek Physician Advice</content>
                        </paragraph>
                        <paragraph>Advise patients that if they develop a new ocular condition (e.g., trauma, infection, or inflammation), experience a sudden decrease in visual acuity, have ocular surgery, or develop any ocular reactions, particularly conjunctivitis and eyelid reactions, they should immediately seek their physician's advice concerning the continued use of Omlonti.</paragraph>
                     </text>
                     <effectiveTime value="20241031"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="335033bf-6912-2053-e063-6394a90a4ef2"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Use with Contact Lenses</content>
                        </paragraph>
                        <paragraph>Contact lenses should be removed prior to administration of the solution. Lenses may be reinserted 15 minutes after administration.</paragraph>
                     </text>
                     <effectiveTime value="20241031"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="335033bf-6913-2053-e063-6394a90a4ef2"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Use with Other Ophthalmic Drugs</content>
                        </paragraph>
                        <paragraph>Advise patients that if more than one topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes apart
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S2">Dosage and Administration (2)</linkHtml>]
 
  </content>.

 </paragraph>
                        <br/>
                     </text>
                     <effectiveTime value="20241031"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="335033bf-6914-2053-e063-6394a90a4ef2"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>Manufactured for:</paragraph>
                  <paragraph>Ocuvex Therapeutics, Inc 
  <br/>  1 Bridge Plaza, 2
 
  <sup>nd</sup>Floor 
  <br/>  Fort Lee, NJ 07024

 </paragraph>
                  <br/>
                  <paragraph>PI-002-01 
  <br/>  Rev 10/2024
 </paragraph>
               </text>
               <effectiveTime value="20241031"/>
            </section>
         </component>
         <component>
            <section ID="id_link_3350424f-c47f-4826-e063-6294a90a165e">
               <id root="3350424f-c47e-4826-e063-6294a90a165e"/>
               <code code="42230-3" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PATIENT PACKAGE INSERT SECTION"/>
               <text>
                  <table border="1" cellpadding="0" cellspacing="0" width="100%" styleCode="Noautorules">
                     <tbody>
                        <tr>
                           <td align="center" valign="top">
                              <paragraph>
                                 <content styleCode="bold">INSTRUCTIONS FOR USE</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" valign="top">
                              <paragraph>
                                 <content styleCode="bold">OMLONTI</content>
                                 <sup>®</sup>
                                 <content styleCode="bold"> [om lon’tee]</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" valign="top">
                              <paragraph>
                                 <content styleCode="bold">(omidenepag isopropyl ophthalmic solution) 0.002%</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" valign="top">
                              <paragraph>
                                 <content styleCode="bold">for topical ophthalmic use</content>
                              </paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>Read this Instructions for Use before you start using Omlonti and each time you get refills. There may be new and updated information. This leaflet does not take the place of talking to your healthcare provider about your medical condition or your treatment.</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM2"/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Important information you need to know before using Omlonti</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>Omlonti is for use in the eye.</item>
                     <item>Use Omlonti exactly as your healthcare provider tells you to use it.</item>
                     <item>After you remove the Omlonti multi-dose bottle from the carton, make sure the tamper-evident overcap is not broken. If the tamper-evident overcap is broken, Omlonti may not be safe for you to use.</item>
                     <item>If you use Omlonti with other eye medicines, you should wait at least 5 minutes between using Omlonti and the other medicines.</item>
                     <item>If you wear contact lenses, remove your contact lenses before using Omlonti. You should wait 15 minutes after using Omlonti before placing your contact lenses back in your eye.</item>
                     <item>Call your healthcare provider right away if you develop new eye problems including: an eye injury, eye infection, eye pain, light sensitivity, blurry vision, decreased vision, swelling and redness of the eye, problems with your eyelids, changes in the appearance of your eyes, headache, or eye surgery.</item>
                     <item>If you develop blurred vision or light sensitivity after using Omlonti, 
   <content styleCode="bold">do not</content>drive or operate heavy machinery until the symptoms disappear.
  </item>
                     <item>Omlonti can cause color changes in your iris and eyelid and may change the length and color of your eyelashes.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Using Omlonti</content>
                  </paragraph>
                  <paragraph>Follow 
  <content styleCode="bold">Step 1</content>to 
  <content styleCode="bold">Step 11</content>each time you use Omlonti. Ask your healthcare provider for help if you do not understand how to use Omlonti.
 </paragraph>
                  <table width="50%">
                     <colgroup>
                        <col align="left" valign="top" width="70%"/>
                        <col align="center" valign="top" width="30%"/>
                     </colgroup>
                     <tbody>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">
                              <content styleCode="bold">Step 1</content>. Wash your hands thoroughly with soap and water. If you cannot wash your hands, you can clean your hands using hand sanitizer.
    </td>
                           <td styleCode="Rrule">
                              <renderMultiMedia referencedObject="MM4"/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">
                              <content styleCode="bold">Step 2</content>. Turn the tamper-evident overcap to the left to open the multi-dose bottle.
    </td>
                           <td styleCode="Rrule">
                              <renderMultiMedia referencedObject="MM5"/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">
                              <content styleCode="bold">Step 3</content>. Remove the tamper-evident overcap and throw it away.
    </td>
                           <td styleCode="Rrule">
                              <renderMultiMedia referencedObject="MM6"/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">
                              <content styleCode="bold">Step 4</content>. Gently shake the bottle.
    </td>
                           <td styleCode="Rrule">
                              <renderMultiMedia referencedObject="MM7"/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">
                              <content styleCode="bold">Step 5</content>. Turn the inner screw cap to the left to remove it. 
     <content styleCode="bold">Do not </content>throw the inner screw cap away.
    </td>
                           <td styleCode="Rrule">
                              <renderMultiMedia referencedObject="MM8"/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">
                              <content styleCode="bold">Step 6</content>. Pull down your lower eyelid with a clean finger. The medicine will go into the space between your lower eyelid and your eye.
    </td>
                           <td styleCode="Rrule">
                              <renderMultiMedia referencedObject="MM9"/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">
                              <content styleCode="bold">Step 7</content>. Tilt your head back and look up.
    </td>
                           <td styleCode="Rrule">
                              <renderMultiMedia referencedObject="MM10"/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">
                              <content styleCode="bold">Step 8</content>. Gently squeeze the multi-dose bottle to release 1 drop of the medicine in your eye. 
     <content styleCode="bold">Do not </content>let the tip of the multi-dose bottle touch your eye or any other surfaces. If a drop misses your eye, try again.
    </td>
                           <td styleCode="Rrule">
                              <renderMultiMedia referencedObject="MM11"/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">
                              <content styleCode="bold">Step 9</content>. Blink a few times so that the medicine spreads across your eye.
    </td>
                           <td styleCode="Rrule">
                              <renderMultiMedia referencedObject="MM12"/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">
                              <content styleCode="bold">Step 10</content>. After using Omlonti, gently close your eyelid and press the corner of your eye closest to your nose for 2 minutes.
    </td>
                           <td styleCode="Rrule">
                              <renderMultiMedia referencedObject="MM13"/>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule">
                              <content styleCode="bold">Step 11</content>. Repeat 
     <content styleCode="bold">Step 6 </content>to 
     <content styleCode="bold">Step 10 </content>for your other eye if you need to use drops in both eyes.
    </td>
                           <td styleCode="Rrule"/>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">Storing Omlonti</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>Store unopened Omlonti in the refrigerator between 36°F to 46°F (2°C to 8°C).</item>
                     <item>After opening, store Omlonti up to 31 days at room temperature between 68°F to 86°F (20° to 30°C).</item>
                     <item>
                        <content styleCode="bold">Do not </content>use Omlonti if the expiration date (EXP YYYY-MM) on the outer carton and multi-dose bottle have passed. The expiration date is the last day of that month.
  </item>
                     <item>After removing the tamper-evident overcap, keep the multi-dose bottle closed with the inner screw cap on to avoid contamination.</item>
                     <item>
                        <content styleCode="bold">Keep Omlonti and all medicines out of the reach of children.</content>
                     </item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Additional Information</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>If you have questions about Omlonti, talk to your healthcare provider, or call Ocuvex Therapeutics Medical Information: 1-877-622-9326.</item>
                  </list>
                  <paragraph>Manufactured for:</paragraph>
                  <paragraph>Ocuvex Therapeutics, Inc
  <br/>
1 Bridge Plaza, 2 
  <sup>nd</sup>Floor
  <br/>
Fort Lee, NJ 07024
 </paragraph>
                  <paragraph>This Instructions for Use has been approved by the U.S. Food and Drug Administration.</paragraph>
                  <paragraph>Approved: 09/2022</paragraph>
                  <paragraph>PIL-002-01 Rev: 10/2024</paragraph>
               </text>
               <effectiveTime value="20241031"/>
               <component>
                  <observationMedia ID="MM2">
                     <text>Image</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="omlonti-ophthalmic-solution-fig-1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM4">
                     <text>Step 1</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="omlonti-ophthalmic-solution-fig-2.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM5">
                     <text>Step 2</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="omlonti-ophthalmic-solution-fig-3.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM6">
                     <text>Step 3</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="omlonti-ophthalmic-solution-fig-4.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM7">
                     <text>Step 4</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="omlonti-ophthalmic-solution-fig-5.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM8">
                     <text>Step 5</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="omlonti-ophthalmic-solution-fig-6.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM9">
                     <text>Step 6</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="omlonti-ophthalmic-solution-fig-7.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM10">
                     <text>Step 7</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="omlonti-ophthalmic-solution-fig-8.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM11">
                     <text>Step 8</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="omlonti-ophthalmic-solution-fig-9.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM12">
                     <text>Step 9</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="omlonti-ophthalmic-solution-fig-10.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM13">
                     <text>Step 10</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="omlonti-ophthalmic-solution-fig-11.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="335033bf-6916-2053-e063-6394a90a4ef2"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 2.5 mL Bottle Label</title>
               <text>
                  <paragraph>NDC 84826-002-01</paragraph>
                  <paragraph>Ocuvex</paragraph>
                  <paragraph>OMLONTI
 
  <sup>®</sup>
                     <br/>  (omidenepag isopropyl 
  <br/>  ophthalmic solution) 0.002%

 </paragraph>
                  <paragraph>FOR TOPICAL USE 
  <br/>  IN THE EYES
 </paragraph>
                  <paragraph>STERILE</paragraph>
                  <paragraph>RX ONLY</paragraph>
                  <paragraph>2.5 mL</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM14"/>
                  </paragraph>
               </text>
               <effectiveTime value="20241031"/>
               <component>
                  <observationMedia ID="MM14">
                     <text>PRINCIPAL DISPLAY PANEL - 2.5 mL Bottle Label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="omlonti-ophthalmic-solution-2pt5ml-bottle-label.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="335033bf-6917-2053-e063-6394a90a4ef2"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 2.5 mL Carton Label</title>
               <text>
                  <paragraph>NDC 84826-002-01</paragraph>
                  <paragraph>Ocuvex</paragraph>
                  <paragraph>OMLONTI
 
  <sup>®</sup>
                     <br/>  (omidenepag isopropyl 
  <br/>  ophthalmic solution) 0.002%

 </paragraph>
                  <paragraph>FOR TOPICAL USE 
  <br/>  IN THE EYES
 </paragraph>
                  <paragraph>STERILE</paragraph>
                  <paragraph>RX ONLY</paragraph>
                  <paragraph>2.5 mL</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM40"/>
                  </paragraph>
               </text>
               <effectiveTime value="20241031"/>
               <component>
                  <observationMedia ID="MM40">
                     <text>PRINCIPAL DISPLAY PANEL - 2.5 mL Carton Label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="omlonti-ophthalmic-solution-2pt5ml-carton-label.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>